(IN BRIEF) AstraZeneca announced positive interim Phase III VOLGA trial results showing that perioperative Imfinzi combined with neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, AstraZeneca Expands Immunotherapy Momentum in Bladder Cancer with Positive Phase III VOLGA Trial Readout, AstraZeneca oncology, bladder cancer, Cancer Immunotherapy, cancer recurrence, cancer treatment, cisplatin-ineligible patients, clinical trial results, CTLA-4, durvalumab, enfortumab vedotin, EV, event-free survival, Imfinzi, Imjudo, immunotherapy, MIBC, muscle-invasive bladder cancer, NIAGARA trial, NILE trial, oncology, oncology research, overall survival, PD-L1 inhibitor, Phase III Trial, POTOMAC trial, radical cystectomy, survival outcomes, Susan Galbraith, Thomas Powles, tremelimumab, urothelial carcinoma, VOLGA Phase III Results Position AstraZeneca’s Imfinzi Regimen as Promising New Option for Cisplatin-Ineligible Bladder Cancer Patients, VOLGA trial
(IN BRIEF) Researchers from The Institute of Cancer Research and Queen’s University Belfast have developed an AI tool to improve the accuracy and consistency of PD-L1 scoring in lung cancer diagnosis. The system uses deep learning to assist pathologists in … Read the full press release
Posted in Artificial Intelligence (AI), Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged artificial intelligence, biomarker analysis, digital pathology, immunotherapy, lung cancer, Manuel Salto-Tellez, non-small cell lung carcinoma, NSCLC, oncology, PD-L1, precision medicine, Queen's University Belfast, Researchers advance digital pathology with new AI solution for more reliable lung cancer diagnostics, Scientific Reports, The Institute of Cancer Research, TPS, Tumour Proportion Score
(IN BRIEF) The European Investment Bank has provided €100 million in financing to Orion Pharma to support the development of new treatments for cancer, pain, and other conditions with limited therapeutic options. The funding will be used for research and … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Finland, Government, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged biopharmaceutical industry, clinical trials, Critical Medicines Alliance, drug development, EIB, EU resilience, European Investment Bank, European Investment Bank and Orion Pharma Expand Collaboration to Boost Healthcare Innovation and Supply Security, Healthcare Innovation, Karl Nehammer, oncology, Orion Pharma, pain treatment, pharmaceutical research, R&D investment, René Lindell, €100 Million EIB Investment Supports Orion Pharma Development of Critical Medicines and Therapies
(IN BRIEF) Eckert & Ziegler has secured MDR certification for its Ru-106 eye applicators, ensuring continued availability of a critical treatment for eye cancer patients in the EU. The devices, used in brachytherapy procedures for conditions such as uveal melanoma … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology
Tagged brachytherapy, Eckert & Ziegler, Eckert & Ziegler BEBIG, Eckert & Ziegler Reinforces Medical Technology Leadership with Approval of Niche Eye Cancer Treatment Devices, European Union, eye applicators, healthcare technology, Katrin Antonenko, MDR Certification, MDR Certification Strengthens Availability of Critical Brachytherapy Devices for Eye Tumor Treatment Across EU, Medical Device Regulation, medical devices, oncology, patient care, radiation therapy, retinoblastoma, Ru 106, uveal melanoma
(IN BRIEF) GSK plc has received Orphan Drug Designation in Japan for its investigational antibody-drug conjugate risvutatug rezetecan (Ris-Rez) for the treatment of small-cell lung cancer, supported by early clinical data showing durable responses in patients with extensive-stage disease. SCLC, … Read the full press release
Posted in Business, Healthcare, Marketing, Pharma & Biotech, Science, Security & Safety, United Kingdom
Tagged antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, clinical trials, colorectal cancer, EMA, ES SCLC, extensive stage SCLC, FDA, GSK, GSK advances investigational cancer therapy risvutatug rezetecan with sixth global designation supporting development in solid tumours, Hansoh Pharma, Japan Ministry of Health Labour and Welfare, lung cancer, oncology, orphan drug designation, Phase III Trial, PRIME designation, prostate cancer, Ris Rez, risvutatug rezetecan, SCLC, Small cell lung cancer
(IN BRIEF) Rīga Stradiņš University (RSU) will host the BFCS 2026 international conference on 19–20 March 2026 in Riga, Latvia, in collaboration with the Baltic Flow Cytometry Society. The two-day event will bring together flow cytometry specialists, clinicians, and researchers … Read the full press release
Posted in Education, Healthcare, Latvia, Pharma & Biotech, Science, Technology
Tagged abstract submission, Baltic Flow Cytometry Society, BFCS, BFCS 2026, biomedical research, clinical research, early-career researchers, flow cytometry, immunology, Institute of Microbiology and Virology, interdisciplinary collaboration, international scientific conference, microbiology, oncology, PhD students, postdoctoral fellows, Riga Latvia, Rīga Stradiņš University, RSU, scientific networking, virology, Young Researcher Awards
(IN BRIEF) GSK announced that its B7-H3-targeted antibody-drug conjugate GSK5764227 (GSK’227) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer (SCLC). The designation is supported … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, cancer research, EMA, EMA Grants Orphan Drug Designation to GSK’s B7-H3 Antibody-Drug Conjugate for Pulmonary Neuroendocrine Carcinoma, FDA, GSK, GSK Strengthens Oncology Pipeline With EMA Orphan Drug Status for GSK’227 in Small-Cell Lung Cancer, GSK5764227, GSK’227, immuno-oncology, lung cancer, NEC, ODD, oncology, oncology pipeline, orphan drug designation, PRIME designation, pulmonary neuroendocrine carcinoma, relapsed or refractory, SCLC, Small cell lung cancer, solid tumours, targeted therapy
Europe’s RNA immunotherapy sector is gaining speed with new in vivo CAR-T and mRNA vaccine trials. Germany approved the region’s first in vivo CAR-T study, marking regulatory progress. The UK’s Cancer Vaccine Launch Pad advances personalised mRNA cancer vaccine trials … Read the full press release
Posted in Belgium, Business, Germany, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, ATMP, autoimmunity, BioNTech, BioNTech’s BNT116, biotechnology, Cancer Vaccine Launch Pad, CAR-T therapy, clinical trials, CREATE Medicines, CureVac, EMA, EU-FAB, Europe, Europe Becomes a Hub for Next-Generation RNA Immunotherapy with Strong Clinical and Industrial Momentum, Europe’s Biotech Sector Accelerates RNA-Based Immunotherapy with Breakthroughs in CAR-T and mRNA Vaccines, Europe’s RNA Immunotherapy Industry Poised for Expansion as BioNTech AstraZeneca and CREATE Medicines Lead Advances, Europe’s RNA Immunotherapy Landscape Expands with First In Vivo CAR-T Trial and Growing mRNA Vaccine Efforts, Europe’s RNA Immunotherapy Pipeline Gains Scale as Regulators and Industry Push for Next-Gen Cancer Treatments, fibrosis, Germany, Imfinzi, immuno-oncology, in vivo CAR-T, INT2104, mRNA Vaccines, multi-lineage immune programming, Myeloid Therapeutics, NHS England, oncology, pharma, RNA immunotherapy, RNA Immunotherapy in Europe: Emerging Trials Strategic Mergers and a Clearer Regulatory Path, RNA Immunotherapy Takes Hold in Europe as BioNTech-CureVac Deal and CREATE Medicines Expansion Signal Maturity, RNA therapeutics, RNA-based therapies, United Kingdom
Rebrand: Myeloid Therapeutics becomes CREATE Medicines, reflecting a shift to multi-lineage RNA immune programming. Scientific Focus: Expanding beyond myeloid cells to include T and NK cells for scalable, redosable in vivo CAR therapies. Clinical Data: Over 40 patients treated with … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, CREATE Medicines Bridges Science Strategy and Investment with Expanded RNA Platform for In Vivo Multi-Immune Therapies in Europe and Beyond, CREATE Medicines Integrates Scientific Progress and Investor Backing to Lead Multi-Lineage RNA Immunotherapy’s Next Chapter in Europe, CREATE Medicines Rebrand Reflects Strategic Expansion into Multi-Lineage RNA Immunotherapy as Europe’s Biotech Sector Embraces In Vivo Therapies, CREATE Medicines Reinforces Its Market and Research Focus Through RNA-Driven Multi-Lineage Immune Programming Amid Rising European Investment in mRNA Therapeutics, CREATE Medicines Strengthens Its Scientific and Strategic Position with Multi-Lineage RNA Platform and Investor Support Across a Growing European Biotech Market, CREATE Medicines’ New Identity Combines RNA-Based Scientific Leadership and Investor Momentum with Expanding Opportunities in European Immunotherapy Markets, CREATE Medicines’ Transition Marks New Phase in RNA Immunotherapy Development and Strategic Growth in Europe’s Expanding Biotech Landscape, Daniel Getts, Daniel Getts Ph.D., fibrosis, Following Its Rebrand, From Myeloid Therapeutics to CREATE Medicines: A Rebrand Uniting RNA Innovation Investor Confidence and Expanding European Immunotherapy Ambitions, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, himeric antigen receptor, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, Rebranded CREATE Medicines Aligns Scientific Innovation and Investor Backing to Advance RNA-Based In Vivo CAR Therapies in Global and European Markets, Rebranded CREATE Medicines Positions Itself at the Forefront of RNA Immunotherapy as Europe’s Biotech Ecosystem Accelerates Innovation, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
(IN BRIEF) FIGO will host over 5,000 participants at the XXV FIGO World Congress of Gynecology and Obstetrics, held in Cape Town, South Africa, from 5–9 October 2025. Returning to Africa for the first time since 2009, the Congress will … Read the full press release
Posted in Awards, Healthcare, Management, News, Science, Society, United Kingdom
Tagged adolescent gynecology, Cape Town, climate change, endometriosis, FIGO, FIGO 2025 Congress Returns to Africa with Global Focus on Innovation Equity and Women’s Wellbeing, FIGO Film Festival, FIGO to Welcome Over 5000 Delegates to XXV World Congress in Cape Town to Advance Global Women’s Health, global health, gynecology, Health Equity, maternal health, menopause, migrant health, newborn health, Obstetrics, oncology, Over 5000 Health Leaders to Gather in Cape Town for FIGO 2025 to Champion Women’s and Girls’ Health, Professor Kihara Anne-Beatrice, Professor Paul Fogarty, reproductive health, reproductive rights, social justice, South Africa, SRHR, transgender care, Women’s Health, XXV FIGO World Congress
CREATE Medicines (“CREATE”) broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, providing clear differentiation among competitors and significant value potential for all stakeholders CREATE Medicines will … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, Daniel Getts, Daniel Getts Ph.D., fibrosis, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review by the FDA for the first-line treatment of HER2-positive metastatic breast cancer. The application is supported by data from the … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, breakthrough therapy designation, cancer treatment innovation, Daiichi Sankyo, DESTINY-Breast09, Enhertu, Enhertu plus pertuzumab moves closer to first-line approval in HER2-positive metastatic breast cancer after FDA Priority Review acceptance, FDA, FDA grants Priority Review to Enhertu plus pertuzumab for 1st-line HER2-positive metastatic breast cancer following DESTINY-Breast09 success, HER2-positive breast cancer, Ken Takeshita, metastatic breast cancer, oncology, pertuzumab, Priority Review, progression-free survival, Real-Time Oncology Review, Susan Galbraith, THP regimen, trastuzumab deruxtecan
(IN BRIEF) GSK announced a $30 billion investment plan across the United States over the next five years, expanding its research, development, and supply chain infrastructure while creating hundreds of skilled jobs. The plan includes a $1.2 billion investment unveiled … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI technologies, asthma, biologics flex factory, biopharma manufacturing, cancer medicines, clinical trials, COPD, digital technologies, drug discovery, Emma Walmsley, GSK, GSK strengthens U.S. presence with next-generation biopharma factories and expanded clinical trial network, life sciences, Marietta Pennsylvania, New $1.2 billion Pennsylvania flex factory part of GSK’s five-year plan to expand American life sciences footprint, oncology, supply chain investment, United Kingdom, United States, Upper Merion Pennsylvania, vaccines, workforce expansion
(IN BRIEF) Cyted Health has raised USD 44 million in Series B financing led by EQT Life Sciences with participation from Advent Life Sciences, the British Business Bank, Morningside, BGF, and HCA Healthcare. The funds will accelerate Cyted’s commercial rollout … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Netherlands, News, Science, Sweden, Technology, United Kingdom
Tagged Advent Life Sciences, BGF, biomarker testing, British Business Bank, Bruno Holthof, Cyted Health, EndoSign, EQT Life Sciences, esophageal cancer, gastroenterology, gastrointestinal diagnostics, HCA Healthcare, Marcel Gehrung, Morningside, NHS, oncology, partnership, Series B funding, sustainability, University of Cambridge, US expansion
(IN BRIEF) Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has received accelerated approval in China for patients with advanced NSCLC carrying HER2 mutations who have progressed after prior therapy. The approval is supported by Beamion-LUNG 1 data, which showed a 71% objective … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AACR 2025, Beamion-LUNG 1, Beamion-LUNG 2, Boehringer Ingelheim, breakthrough therapy designation, CHINA, HER2 mutations, HERNEXEOS, New England Journal of Medicine, NMPA approval, non-small cell lung cancer, NSCLC, oncology, partnership, Shashank Deshpande, targeted therapy, tyrosine kinase inhibitor, Wu Yilong, zongertinib
(IN BRIEF) GSK has entered into a multi-programme development and licensing agreement with Hengrui Pharma to advance up to 12 innovative therapies, including HRS-9821, a potentially best-in-class PDE3/4 inhibitor currently in clinical trials for COPD. The deal includes $500 million … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AI-era medicine, biopharma partnership, Chronic obstructive pulmonary disease, clinical development, cloud healthcare, COPD treatment, drug innovation, drug pipeline, dry powder inhaler, Frank Jiang, global health, GSK, Hart-Scott-Rodino Act, Hengrui Pharma, HRS-9821, immunology, inflammation, licensing agreement, milestone payments, novel therapeutics, oncology, partnership, PDE3/4 inhibitor, pharmaceutical collaboration, phase I trials, respiratory medicine, Tony Wood
(IN BRIEF) AstraZeneca’s Trixeo Aerosphere has received a positive opinion from the EMA’s CHMP for use with a new propellant that offers a 99.9% reduction in Global Warming Potential compared to traditional formulations. Trixeo becomes the first pressurised metered-dose inhaler … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Ambition Zero Carbon, AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, Breztri, BTK inhibitor, budesonide, Calquence, chemoimmunotherapy, CHMP, chronic lymphocytic leukaemia, climate action in pharma, clinical trial, CLL, COPD, Dave Fredrickson, EMA, environmental sustainability, European approval, European Commission approval, European Union, fixed-duration regimen, formoterol fumarate, Frederik Trinkmann, glycopyrronium, hematologic diseases, hematology, Honeywell, inhalers, leukemia, low GWP, next-generation propellant, obinutuzumab, oncology, pMDI, progression-free survival, Respiratory Care, Ruud Dobber, Susanna Palkonen, Sustainable Healthcare, treatment option, Trixeo Aerosphere, venetoclax
(IN BRIEF) Sanofi has secured European Commission approval for Sarclisa in combination with VRd as an induction treatment for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant. The decision was based on part one of the GMMG-HD7 … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged autologous stem cell transplant, bortezomib, cancer treatment, clinical trials, dexamethasone, EU approval, front-line therapy, German-speaking Myeloma Multicenter Group, GMMG-HD7, hematologic malignancies, ICARIA-MM, IKEMA, IMROZ, isatuximab, lenalidomide, MRD negativity, Multiple Myeloma, Olivier Nataf, oncology, progression-free survival, Sanofi, Sarclisa, transplant-eligible, VRd
(IN BRIEF) Final overall survival results from AstraZeneca’s FLAURA2 Phase III trial confirm that combining Tagrisso with chemotherapy significantly improves survival for patients with first-line advanced EGFR-mutated NSCLC. The data reinforce Tagrisso as the foundational therapy in this setting, building … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADAURA trial, ADAURA2, adjuvant therapy, AstraZeneca, cancer survival, chemotherapy, EGFRm NSCLC, EMA, FDA, FLAURA2 trial, global clinical trial, LAURA trial, lung cancer treatment, NeoADAURA, non-small cell lung cancer, oncology, osimertinib, overall survival, Pasi A. Jänne, pemetrexed, platinum-based treatment, progression-free survival, Susan Galbraith, Tagrisso, targeted therapy
(IN BRIEF) AstraZeneca’s Calquence, in combination with venetoclax, with or without obinutuzumab, has been approved by the European Commission for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The approval follows the positive results from the … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, BTK inhibitor, Calquence, chemoimmunotherapy, chronic lymphocytic leukaemia, clinical trial, CLL, Dave Fredrickson, European Commission approval, European Union, fixed-duration regimen, hematologic diseases, hematology, leukemia, obinutuzumab, oncology, progression-free survival, treatment option, venetoclax
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?